Article
Rheumatology
Siddharth Jain, Varun Dhir, Amita Aggarwal, Ranjan Gupta, Bidyalaxmi Leishangthem, Shankar Naidu, Aastha Khullar, Supriya Maurya, Veena Dhawan, Shefali Khanna Sharma, Aman Sharma, Sanjay Jain
Summary: This study compared the efficacy and safety of different dose escalation strategies of oral MTX in RA patients over a period of 16-24 weeks. The results showed that a faster escalation strategy was not more effective than the usual strategy, but was associated with higher gastrointestinal adverse events in the initial phase.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Mikkel Ostergaard, Ronald F. van Vollenhoven, Anna Rudin, Merete Lund Hetland, Marte Schrumpf Heiberg, Dan C. Nordstrom, Michael T. Nurmohamed, Bjorn Gudbjornsson, Lykke Midtboll Ornbjerg, Pernille Boyesen, Kristina Lend, Kim Horslev-Petersen, Till Uhlig, Tuulikki Sokka, Gerdur Grondal, Simon Krabbe, Joakim Lindqvist, Inger Gjertsson, Daniel Glinatsi, Meliha Crnkic Kapetanovic, Anna-Birgitte Aga, Francesca Faustini, Pinja Parmanne, Tove Lorenzen, Cagnotto Giovanni, Johan Back, Oliver Hendricks, Daisy Vedder, Tuomas Rannio, Emma Grenholm, Maud Kristine Ljosa, Eli Brodin, Hanne Lindegaard, Annika Soderbergh, Milad Rizk, Alf Kastbom, Per Larsson, Line Uhrenholt, Soren Andreas Just, David J. Stevens, Trine Bay Laurbjerg, Gunnstein Bakland, Inge Christoffer Olsen, Espen A. Haavardsholm, Jon Lampa, NORD-STAR Study Grp
Summary: This study compared the clinical and radiographic outcomes of different biological treatments with active conventional therapy in patients with early rheumatoid arthritis (RA). The results showed that abatacept and certolizumab pegol had higher clinical remission rates compared to active conventional therapy, while tocilizumab did not show significant differences. Radiographic progression was low and similar across treatments.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Carlo Scognamiglio Renner Araujo, Ana Cristina Medeiros-Ribeiro, Carla G. S. Saad, Karina Rossi Bonfiglioli, Diogo Souza Domiciano, Andrea Yukie Shimabuco, Matheus Santos Rodrigues Silva, Emily Figueiredo Neves Yuki, Sandra Gofinet Pasoto, Tatiana Pedrosa, Leonard de Vinci Kanda Kupa, Gioanna Zou, Rosa M. R. Pereira, Clovis Artur Silva, Nadia Emi Aikawa, Eloisa Bonfa
Summary: This study evaluated the effect of discontinuing methotrexate (MTX) for 2 weeks after each dose of the Sinovac-CoronaVac vaccine on immunogenicity and safety in patients with rheumatoid arthritis (RA). The results showed that the group that discontinued MTX had a higher rate of seroconversion and higher antibody titers compared to the group that continued MTX. However, there was an increased risk of flare after the second MTX withdrawal.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Andreas Kerschbaumer, Zaida Iasha Rivai, Josef S. Smolen, Daniel Aletaha
Summary: This study analyzed the response differences in patients with rheumatoid arthritis receiving placebo treatment, comparing those who continued background therapy with methotrexate (MTX) and those without any disease modifying antirheumatic drugs (DMARDs). The results showed that placebo responses were higher in patients who continued MTX background therapy, suggesting a more consequent intake of background therapy during the trial period.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Pharmacology & Pharmacy
Karel Hloch, Martin Dosedel, Jurjen Duintjer Tebbens, Lenka Zaloudkova, Helena Medkova, Jiri Vlcek, Tomas Soukup, Petr Pavek
Summary: Patients with rheumatoid arthritis who discontinue methotrexate treatment are at a significantly higher risk of cardiovascular diseases and all-cause mortality, highlighting the importance of stricter cardiovascular disease control in cases of methotrexate discontinuation.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Biophysics
Tais Monteiro Magne, Edward Helal-Neto, Luana Barbosa Correa, Luciana Magalhaes Rebelo Alencar, Sara Gemini Piperni, Surtaj H. Iram, Prapanna Bhattarai, Lin Zhu, Eduardo Ricci-Junior, Maria das Gracas Muller de Oliveira Henriques, Elaine Cruz Rosas, Ralph Santos-Oliveira
Summary: Rheumatoid arthritis is a common autoimmune disease affecting joints causing inflammation and swelling, significantly impacting quality of life and mortality. The use of drug-loaded nanomicelles showed a 2-fold higher therapeutic effect in modulating the inflammatory process of RA.
COLLOIDS AND SURFACES B-BIOINTERFACES
(2021)
Article
Nanoscience & Nanotechnology
Jiayao Lyu, Lujun Wang, Xiaosheng Bai, Xingjie Du, Jun Wei, Jianxin Wang, Yan Lin, Zhenyu Chen, Zhongbing Liu, Jianming Wu, Zhirong Zhong
Summary: This study successfully loaded methotrexate (MTX) into nanoparticles of human serum albumin modified with mannose for targeted drug delivery to neutrophils, reducing toxicity and showing significant anti-inflammatory, antiangiogenic, and anti-arthritic effects in experimental models. The nanoparticles prolonged the in vivo circulation of MTX and accumulated mainly in arthritic joints, indicating their potential as a useful drug delivery system for rheumatoid arthritis.
ACS APPLIED MATERIALS & INTERFACES
(2021)
Article
Rheumatology
Paul Studenic, Daniel Aletaha, Maarten de Wit, Tanja A. Stamm, Farideh Alasti, Diane Lacaille, Josef S. Smolen, David T. Felson
Summary: This study aimed to externally validate a revised Boolean remission criteria using a higher patient global assessment (PtGA) threshold and validate the provisionally endorsed index-based criteria. The results showed that using the higher PtGA threshold increased the proportion of patients classified as achieving remission under the "Boolean2.0" criteria, improved agreement with index-based criteria, and did not compromise predictive value for radiographic or functional outcomes. The study findings were endorsed by ACR and EULAR.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Immunology
Liyan Mei, Zhihua Yang, Xiaolin Zhang, Zehao Liu, Maojie Wang, Xiaodong Wu, Xiumin Chen, Qingchun Huang, Runyue Huang
Summary: This study investigated the changes in gut microbiome of RA patients treated with HQT or LEF, revealing significant differences in gut microbiota between RA patients and healthy controls. The clinical efficacy of the two treatments was similar, but the response trends of RA-related clinical indices differed between the two treatment groups.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, Research & Experimental
Jinzhang Gao, Ning Xiao, Qianlei Wang, Zhengkun Xu, Feng Xiao, Zhaoyi Yang, Wei Wei, Chun Wang
Summary: The study found that OAT3 plays a crucial role in the development of MTX resistance in the treatment of rheumatoid arthritis, serving as a potential target to improve the resistance.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Engineering, Biomedical
Xingliang Liu, Shi Chen, Yanzi Yan, Lixin Liu, Yongming Chen
Summary: In this study, cationic nanoparticles with MMP2-sensitive peptide were designed to alleviate the symptoms of rheumatoid arthritis by scavenging cfDNA. The engineered nanoparticles exhibited lower toxicity, longer retention time, and higher accumulation in inflamed joints compared to their counterparts. The anti-inflammatory activity of MTX further enhanced the therapeutic efficacy of the nanoparticles.
Article
Rheumatology
Renske C. F. Hebing, Marry Lin, Maja Bulatovic Calasan, Ittai B. Muller, Sohaila Mahmoud, Sandra Heil, Eduard A. Struys, Bart J. F. van den Bemt, Jos W. R. Twisk, Willem Lems, Michael T. Nurmohamed, Gerrit Jansen, Robert de Jonge
Summary: This study investigates the pharmacokinetics of methotrexate polyglutamate (MTX-PG) accumulation in red blood cells (RBCs) and peripheral blood mononuclear cells (PBMCs) in patients with early rheumatoid arthritis (RA) after oral and subcutaneous MTX treatment. The results show that there are disparate pharmacokinetic profiles between PBMCs and RBCs, with higher accumulation of MTX-PG in PBMCs. The distribution profile of MTX-PG in PBMCs remains constant over 6 months, while in RBCs, the main PG-moiety changes from MTX-PG(1) to MTX-PG(3).
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Ulf Lindstrom, Daniela di Giuseppe, Sofia Exarchou, Gerd-Marie Alenius, Tor Olofsson, Eva Klingberg, Lennart Jacobsson, Johan Askling, Johan K. Wallman
Summary: This study aimed to compare the treatment outcomes of patients with newly diagnosed psoriatic arthritis (PsA) and rheumatoid arthritis (RA) using methotrexate (MTX) monotherapy. The results showed that PsA patients were less likely to continue the use of MTX compared to RA patients, and the effectiveness of MTX was also lower in PsA.
Article
Medicine, General & Internal
Edyta Majorczyk, Malgorzata Mazurek-Mochol, Andrzej Pawlik, Piotr Kusnierczyk
Summary: In this study, we examined 312 patients with rheumatoid arthritis and found that older age at disease onset, low ESR, no erosive disease, and negative RF were independent factors associated with a good response to methotrexate treatment. However, younger age at disease onset, the presence of RF, erosive disease, and a high level of ESR were associated with a worse response to methotrexate therapy.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Kayalvizhi Rajendran, Suman Pahal, Kedar Badnikar, Manjunatha M. Nayak, Dinesh N. Subramanyam, Praveen K. Vemula, Uma Maheswari Krishnan
Summary: Arthritis is an inflammatory disorder that severely affects mobility. Existing treatments have limited effectiveness, and lack of adherence to therapeutic regimen worsens the condition. This study develops a microneedle patch that allows sustained release of an anti-arthritic drug at the site of inflammation, leading to faster restoration of mobility and reduction in inflammatory markers. The results demonstrate the potential of microneedle-based platform for effective arthritic therapy.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Letter
Rheumatology
Katerina Chatzidionysiou, Evangelia Samoli, Petros P. Sfikakis, Maria G. Tektonidou
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Elias Jonsson, Lotta Ljung, Eva Norrman, Eva Freyhult, Lisbeth Arlestig, Johanna Dahlqvist, Solbritt Rantapaa Dahlqvist
Summary: This study assessed the association between pulmonary fibrosis (PF) and genetic variants and disease-related factors in rheumatoid arthritis (RA) patients. The results showed that PF in RA patients is associated with four genetic variants. Older age and RF positivity are associated with increased risk, while MTX treatment is associated with a lower risk of PF development.
Article
Rheumatology
Benedicte Delcoigne, Lotta Ljung, Sella A. Provan, Bente Glintborg, Merete Lund Hetland, Kathrine Lederballe Gron, Ritva Peltomaa, Heikki Relas, Carl Turesson, Bjorn Gudbjornsson, Brigitte Michelsen, Johan Askling
Summary: This study compared the incidence of acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA) starting different biologic disease-modifying antirheumatic drugs (bDMARDs) for 1 year, 2 years, and 5 years, and compared the results with the general population. The findings showed that the risk of ACS remained elevated in patients with RA initiating bDMARDs compared to the general population. The differences in short-term, intermediate-term, and longer-term risks of ACS were minimal across individual bDMARDs.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Review
Medicine, Research & Experimental
Anders Kirkegaard Jensen, Katerina Chatzidionysiou, Christopher Kirkegaard Torp, Anne Sofie Sorensen, Helene Broch Tenstad, Valentin S. Schafer, Marie Kostine, Soren Jacobsen, Jan Leipe, Tue Wenzel Kragstrup
Summary: This literature review compares the pharmacological management of immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) and reactive arthritis (ReA). The studies suggest that non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids (GC), methotrexate (MTX), sulfasalazine (SSZ), and tumor necrosis factor alpha inhibition (TNFi) have shown effectiveness in both diseases.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Rheumatology
Mikael Brink, Lotta Ljung, Monika Hansson, Johan Ronnelid, Rickard Holmdahl, Karl Skriner, Guy Serre, Lars Klareskog, Solbritt Rantapaa-Dahlqvist
Summary: This study found that the presence of certain ACPA and the number of ACPA specificities were associated with the development of PF in early RA patients. These findings contribute to a better understanding of the mechanisms and risk factors for PF development in RA patients.
Article
Rheumatology
Kristina Hornberg, Lotta Ljung, Anna Sodergren, Bjoern Sundstrom
Summary: This study aimed to investigate the deterioration of spinal mobility over time in patients with ankylosing spondylitis (AS) and compare it with corresponding age-related normal values. The results showed that the decline in spinal mobility in AS patients mainly occurred during the first few years of the disease, indicating a narrow window of opportunity for prevention.
ARTHRITIS CARE & RESEARCH
(2023)
Meeting Abstract
Rheumatology
M. Brink, L. Ljung, M. Hansson, J. Ronnelid, R. Holmdahl, K. Skriner, G. Serre, L. Klareskog, S. Rantapaa Dahlqvist
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Meeting Abstract
Rheumatology
D. Di Giuseppe, U. Lindstrom, J. K. Wallman, L. Ljung, J. Askling
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Zara Izadi, Milena A. Gianfrancesco, Gabriela Schmajuk, Lindsay Jacobsohn, Patricia Katz, Stephanie Rush, Clairissa Ja, Tiffany Taylor, Kie Shidara, Maria Danila, Katherine D. Wysham, Anja Strangfeld, Elsa F. Mateus, Kimme L. Hyrich, Laure Gossec, Loreto Carmona, Saskia Lawson-Tovey, Lianne Kearsley-Fleet, Martin Schaefer, Samar Al-Emadi, Jeffrey A. Sparks, Tiffany Y-T Hsu, Naomi J. Patel, Leanna Wise, Emily Gilbert, Ali Duarte-Garcia, Maria O. Valenzuela-Almada, Manuel F. Ugarte-Gil, Lotta Ljung, Carlo A. Scire, Greta Carrara, Eric Hachulla, Christophe Richez, Patrice Cacoub, Thierry Thomas, Maria J. Santos, Miguel Bernardes, Rebecca Hasseli, Anne Regierer, Hendrik Schulze-Koops, Ulf Mueller-Ladner, Guillermo Pons-Estel, Romina Tanten, Romina E. Nieto, Cecilia N. Pisoni, Yohana S. Tissera, Ricardo Xavier, Claudia D. Lopes Marques, Gecilmara C. S. Pileggi, Philip C. Robinson, Pedro M. Machado, Emily Sirotich, Jean W. Liew, Jonathan S. Hausmann, Paul Sufka, Rebecca Grainger, Suleman Bhana, Monique Gore-Massy, Zachary S. Wallace, Jinoos Yazdany
Summary: This study investigated the associations between environmental and societal factors and country-level variations in mortality attributed to COVID-19 among people with rheumatic disease. The findings suggest that air pollution, proportion of the population aged 65 years or older, and population mobility are independently associated with higher odds of mortality. Factors such as number of hospital beds, human development index, government response stringency, and follow-up time are independently associated with lower odds of mortality.
LANCET RHEUMATOLOGY
(2022)
Article
Rheumatology
Katerina Chatzidionysiou, Daniela di Giuseppe, Jonas Soderling, Anca Catrina, Johan Askling
Summary: The study found that patients with RA have a significantly increased risk of developing lung cancer, even after adjusting for smoking. Additionally, rheumatoid factor positivity also contributes to an increased incidence of lung cancer.
Article
Rheumatology
Anna Sodergren, Solbritt Rantapaa-Dahlqvist, Lotta Ljung
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
(2023)
Article
Rheumatology
M-l Karlsson, K. Hertzberg-Nyquist, S. Saevarsdottir, I. E. Lundberg, I Demmelmaier, S. Pettersson, K. Chatzidionysiou
Summary: The objective of this study was to evaluate an individually tailored smoking-cessation intervention in rheumatology care and compare characteristics of patients who quit smoking with those who did not. The results showed that 21% of patients quit smoking after 24 months, with a significant reduction in the number of cigarettes per day for those who still smoked. Patients with anxiety were less successful in quitting smoking.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
(2023)
Article
Immunology
Martina Frodlund, Per Nived, Aikaterini Chatzidionysiou, Anna Sodergren, Eva Klingberg, Anders Bengtsson, Monika Hansson, Sophie Olsson, Elisa Pin, Lars Klareskog, Meliha C. Kapetanovic
Summary: This study aimed to investigate antibody responses in patients with inflammatory rheumatic diseases (IRD) treated with biologic/targeted disease modifying anti-rheumatic drugs (b/ts DMARDs) after the second and third dose of COVID-19 vaccine. The results showed that the percentage of patients with positive antibody response was significantly lower after two doses in patients receiving rituximab or abatacept treatment. However, the antibody response improved after the third dose.
Review
Rheumatology
Celeste J. T. van der Togt, Bart van den Bemt, Daniel Aletaha, Rieke Alten, Katerina Chatzidionysiou, James Galloway, John Isaac, Denis Mulleman, P. Verschueren, Arnold G. Vulto, Paco M. J. Welsing, Lise Verhoef, Alfons A. den Broeder
Summary: The objective of this study was to develop evidence-based points to consider for cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases.
Article
Rheumatology
Louise Hedenstierna, Anna Karin Hedstrom, Lars Klareskog, Daniela Di Giuseppe, Lars Alfredsson, Johan Askling, Sofia Ernestam, Saedis Saevarsdottir, Lotta Ljung
Summary: In early rheumatoid arthritis patients, there is no significant association between psychosocial vulnerability (low social support or low decision latitude at work) and disease remission.
ARTHRITIS RESEARCH & THERAPY
(2022)